JPWO2020160336A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160336A5 JPWO2020160336A5 JP2021541152A JP2021541152A JPWO2020160336A5 JP WO2020160336 A5 JPWO2020160336 A5 JP WO2020160336A5 JP 2021541152 A JP2021541152 A JP 2021541152A JP 2021541152 A JP2021541152 A JP 2021541152A JP WO2020160336 A5 JPWO2020160336 A5 JP WO2020160336A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- smg
- composition
- smu
- sm5c
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800409P | 2019-02-01 | 2019-02-01 | |
| US62/800,409 | 2019-02-01 | ||
| US201962911335P | 2019-10-06 | 2019-10-06 | |
| US62/911,335 | 2019-10-06 | ||
| PCT/US2020/015971 WO2020160336A1 (en) | 2019-02-01 | 2020-01-30 | Oligonucleotide compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519019A JP2022519019A (ja) | 2022-03-18 |
| JPWO2020160336A5 true JPWO2020160336A5 (he) | 2023-02-08 |
Family
ID=71840465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541152A Pending JP2022519019A (ja) | 2019-02-01 | 2020-01-30 | オリゴヌクレオチド組成物及びその方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220098585A1 (he) |
| EP (1) | EP3917497A4 (he) |
| JP (1) | JP2022519019A (he) |
| KR (1) | KR20210121199A (he) |
| CN (1) | CN113423385A (he) |
| AU (1) | AU2020216186A1 (he) |
| BR (1) | BR112021014940A2 (he) |
| CA (1) | CA3126845A1 (he) |
| IL (1) | IL284882A (he) |
| MA (1) | MA54875A (he) |
| MX (1) | MX2021009178A (he) |
| SG (1) | SG11202107318YA (he) |
| TW (1) | TW202045189A (he) |
| WO (1) | WO2020160336A1 (he) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| EP3544987A4 (en) | 2016-11-23 | 2020-11-18 | Wave Life Sciences Ltd. | COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES |
| EP3630789A4 (en) | 2017-06-02 | 2021-06-16 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND THEIR METHODS OF USE |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN111051281A (zh) | 2017-06-21 | 2020-04-21 | 波涛生命科学有限公司 | 用于合成的化合物、组合物和方法 |
| CA3072076A1 (en) | 2017-08-08 | 2019-02-14 | Chandra Vargeese | Oligonucleotide compositions and methods thereof |
| SG11202000276YA (en) | 2017-09-18 | 2020-04-29 | Wave Life Sciences Ltd | Technologies for oligonucleotide preparation |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE |
| JP7317029B2 (ja) | 2018-02-12 | 2023-07-28 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | 修飾化合物及びその使用 |
| CN115038789A (zh) | 2019-12-02 | 2022-09-09 | 塑造治疗公司 | 治疗性编辑 |
| AR125230A1 (es) | 2021-03-29 | 2023-06-28 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
| WO2023076450A2 (en) * | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024035946A1 (en) * | 2022-08-11 | 2024-02-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2176256A1 (en) * | 1993-11-16 | 1995-05-26 | Lyle John Arnold, Jr. | Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages |
| WO2010118263A1 (en) * | 2009-04-08 | 2010-10-14 | University Of Massachusetts | Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease |
| US9006198B2 (en) * | 2010-02-08 | 2015-04-14 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| US20140303235A1 (en) * | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| EP4086347A3 (en) * | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA45270A (fr) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| CA3072076A1 (en) * | 2017-08-08 | 2019-02-14 | Chandra Vargeese | Oligonucleotide compositions and methods thereof |
-
2020
- 2020-01-30 AU AU2020216186A patent/AU2020216186A1/en active Pending
- 2020-01-30 KR KR1020217027787A patent/KR20210121199A/ko unknown
- 2020-01-30 MX MX2021009178A patent/MX2021009178A/es unknown
- 2020-01-30 MA MA054875A patent/MA54875A/fr unknown
- 2020-01-30 CA CA3126845A patent/CA3126845A1/en active Pending
- 2020-01-30 EP EP20748395.9A patent/EP3917497A4/en active Pending
- 2020-01-30 BR BR112021014940-6A patent/BR112021014940A2/pt unknown
- 2020-01-30 US US17/426,511 patent/US20220098585A1/en active Pending
- 2020-01-30 CN CN202080011722.0A patent/CN113423385A/zh active Pending
- 2020-01-30 JP JP2021541152A patent/JP2022519019A/ja active Pending
- 2020-01-30 WO PCT/US2020/015971 patent/WO2020160336A1/en unknown
- 2020-01-30 SG SG11202107318YA patent/SG11202107318YA/en unknown
- 2020-01-31 TW TW109103034A patent/TW202045189A/zh unknown
-
2021
- 2021-07-15 IL IL284882A patent/IL284882A/he unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020160336A5 (he) | ||
| AU2016334232B2 (en) | Oligonucleotide compositions and methods thereof | |
| EP3324978A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP5048575B2 (ja) | オリゴヌクレオチドの脱シリル化の方法 | |
| JP2019214587A5 (he) | ||
| JP2021074021A5 (he) | ||
| CA2726260C (fr) | Procede de synthese d'arn par voie chimique | |
| JP7164540B2 (ja) | 立体的に規定されたホスホロチオエートオリゴヌクレオチドの調製のための直交保護基 | |
| WO1998008858A1 (en) | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages | |
| WO2019182037A1 (ja) | 毒性が低減されたアンチセンスオリゴヌクレオチド | |
| JPH05505101A (ja) | オリゴヌクレオチド療法における三重らせん形成 | |
| JPH09511250A (ja) | 核酸治療に有用な修飾オリゴヌクレオチド及び中間体 | |
| JPH07505904A (ja) | オリゴヌクレオチド類を開裂及び脱保護する方法及び試薬 | |
| JP6730932B2 (ja) | リン保護基ならびにそれらの調製方法および使用 | |
| RU2020130258A (ru) | Способ получения шпилечной одноцепочечной молекулы рнк | |
| KR20230041975A (ko) | Tdt-기반 효소적 핵산을 위한 기질로서의 염기-변형된 뉴클레오티드 | |
| WO1995031434A1 (en) | Complementary dna and toxins | |
| Danielsen et al. | Gapmer Antisense Oligonucleotides Containing 2′, 3′‐Dideoxy‐2′‐fluoro‐3′‐C‐hydroxymethyl‐β‐d‐lyxofuranosyl Nucleotides Display Site‐Specific RNase H Cleavage and Induce Gene Silencing | |
| JP7198768B2 (ja) | ＵｎｙＬｉｎｋｅｒ迅速切断方法 | |
| RU2021124219A (ru) | Композиции на основе олигонуклеотидов и способы, связанные с ними | |
| KR20070101870A (ko) | 올리고뉴클레오티드의 정제 | |
| JP2022120380A (ja) | ｍｉＲＮＡ１３３－ｂ誘導体及びその利用 | |
| Laikhter et al. | The Chemical Synthesis of Oligonucleotides | |
| WO1998033806A1 (en) | Base protecting groups and process for oligonucleotide synthesis | |
| RU2020118025A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ их получения и применения |